GlaxoSmithKline: starts late-stage trial of RSV vaccine
(CercleFinance.com) - GlaxoSmithKline said on Tuesday it is starting a clinical trial of up to 1650 patients to test whether its experimental respiratory syncytial virus (RSV) safely protects older people from the disease.
The Phase III study will assess the safety and long-term persistence of immune response up to three years following vaccination in adults aged 60 years and above, GSK said.
The drugmaker explained that RSV represents a significant health threat for adults who are over 60 years old, with 360,000 hospitalisations and 24,000 deaths each year in developed countries.
Copyright (c) 2021 CercleFinance.com. All rights reserved.
The Phase III study will assess the safety and long-term persistence of immune response up to three years following vaccination in adults aged 60 years and above, GSK said.
The drugmaker explained that RSV represents a significant health threat for adults who are over 60 years old, with 360,000 hospitalisations and 24,000 deaths each year in developed countries.
Copyright (c) 2021 CercleFinance.com. All rights reserved.